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Background: Chronic hepatitis B is a primary cause of liver-related death. Interferon alpha (IFN-α) is able to inhibit
the replication of hepadnavirus, and the sustained and stable expression of IFN-α at appropriate level may be
beneficial to HBV clearance. With the development of molecular cloning technology, gene therapy plays a more
and more important role in clinical practice. In light of the findings, an attempt to investigate the anti-HBV effects
mediated by a eukaryotic expression plasmid (pSecTagB-IFN-α) in vitro was carried out.
Methods: HBV positive cell line HepG2.2.15 and its parental cell HepG2 were transfected with pSecTagB-IFN-α or
empty plasmid by using Lipofectamine™ 2000 reagent. The expression levels of IFN-α were determined by reverse
transcriptase polymerase chain reaction (RT-PCR) and ELISA methods. The effects of pSecTagB-IFN-α on HBV mRNA,
DNA and antigens were analyzed by real-time fluorescence quantitative PCR (qRT-PCR) and ELISA assays. RT-PCR,
qRT-PCR and western blot were employed to investigate the influence of pSecTagB-IFN-α on IFN-α-induced signal
pathway. Furthermore, through qRT-PCR and ELISA assays, the suppressive effects of endogenously expressed IFN-α
and the combination with lamivudine on HBV were also examined.
Results: pSecTagB-IFN-α could express efficiently in hepatoma cells, and then inhibited HBV replication, characterized
by the decrease of HBV S gene (HBs) and HBV C gene (HBc) mRNA, the reduction of HBV DNA load, and the low
contents of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Mechanism research showed that
the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signal pathway, the up-
regulation of IFN-α-induced antiviral effectors and double-stranded (ds) RNA sensing receptors by delivering pSecTagB-
IFN-α, could be responsible for these phenomena. Furthermore, pSecTagB-IFN-α vector revealed effectively anti-HBV
effect than exogenously added IFN-α. Moreover, lamivudine combined with endogenously expressed IFN-α exhibited
stronger anti-HBV effect than with exogenous IFN-α.
Conclusion: Our results showed that endogenously expressed IFN-α can effectively and persistently inhibit HBV
replication in HBV infected cells. These observations opened a promising way to design new antiviral genetic
engineering drugs based on IFN-α.
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Hepatitis B virus (HBV) infection is a serious problem of
public health with about 400 million HBV carriers world-
wide. HBV-induced hepatocellular carcinoma (HCC) and
cirrhosis have made it become a major cause of liver-
related mortality, leading to one million deaths annually
[1]. Immune aggression to HBV-infected cells is the main
reason for liver injury and pathological progression during
viral infection. The purpose of drug treatment for chronic
hepatitis B (CHB) is to suppress HBV replication steadily,
recover normal immune response and delay the progres-
sion of liver pathological process [2]. At present, there are
two major kinds of drugs used for HBV treatment: (I) nu-
cleoside analogues and (II) IFN-α and its derivates [3]. Nu-
cleoside analogues (e.g., lamivudine, telbuvidine and
adefovir,) directly inhibit HBV DNA synthesis and de-
crease viral replication. But this therapy must last for a
long time, resulting in high cost. Furthermore, drug resist-
ance will be induced in most patients during long-term ap-
plication of nucleoside analogues. An increasing durability
of treatment response can be achieved by IFN-α, a cyto-
kine with antiviral and immunoregulatory functions [4].
Many studies have shown that IFN-α plays an import-
ant role in inhibiting viral replication by up-regulating
many antiviral proteins, such as 2′-5′oligoadenylate
synthetase (2′-5′-OAS)/endoribonuclease L (RNase L),
interferon stimulated gene 56 (ISG56) family, APOBEC3
family, and Mx family proteins [5]. Cellular toll-like re-
ceptors (TLR), RIG-I-like receptors (RLR), and nucleo-
tide organization domain-like receptors (NLR) can sense
danger- and pathogen-associated RNAs. The detection
of these RNAs will activate many signal pathways to
induce interferon production. In turn, interferon binds
its receptor will initiate signaling and lead to the up-
regulation of these RNA receptors, promoting the clear-
ance of non-self RNAs. Finally, these processes result
in signaling cascade and further promote the induction
of interferon to clear the invading pathogens [6]. In case
an antiviral state is induced in the infected cells, viral
nucleic acid or protein synthesis will be suppressed, and
cell apoptosis may be initiated, and the invading HBV
virus will be hardly able to replicate in hepatocytes [7].
In addition, type I IFN can activate various immune
cells, including NK cells, NKT cells and DC cells [8],
and up-regulate the expression of major histocompati-
bility complex class I(MHC-I) molecules, triggering the
effective antiviral immune reactions [9]. However, var-
iety of HBV derived protein components can interfere
with the signal pathway of IFN-α by different ways [10],
and part of HBV patients are unable to respond to con-
ventional IFN-α therapy [11]. Therefore, the lasting and
stable expression of IFN-α at appropriate level may en-
hance the local hepatic immune response and improve
the curative effect of IFN-α.Now, there are two major forms of IFN-α in the mar-
ket: ordinary interferon and Peg-IFN-α [12]. The half-
life of ordinary interferon is short, so patients have to
accept regular intramuscular injection or subcutaneous
injection. Peg-IFN-α enhances the half-life of the inter-
feron in serum and improved its bioavailability; however,
PEG reduces the specific activity of IFN-α by reducing
receptor affinity and subsequent biopotency [13]. No
matter what the type of IFN-α is, flu-like symptoms such
as headache, muscle aches, chills and fever, will occur
with each injection. These adverse reactions can range
from minor to serious, and happen in more than half of
patients [14]. Therefore, developing a novel IFN-α dos-
age form or liver-targeted drug delivery system is a new
strategy to improve its curative effect.
So far, there are a lot of successful explorations about
targeted delivery and in situ gene expression in the field
of gene therapy [15]. Treatment of primary hepatocytes
from woodchuck hepatitis virus (WHV)-infected wood-
chucks with an adenoviral vector encoding woodchuck
specific IFN-α (wIFN-α) resulted in the suppression of
WHV replication [16]. Moreover, the woodchucks rem-
edied by intrahepatic injection of a high-capacity adeno-
viral vector encoding murine IL-12, showed a reduction
of hepatic WHV DNA load, a decrease of surface anti-
gen and e antigen [17]. In addition, IFN-α delivered by
T-cell Receptor-Like antibodies could restrain HBV rep-
lication in hepatocytes [18]. So, we hypothesized that
human IFN-α gene carried by an expressing vector
might be a strategy to increase the efficacy of IFN-α-
based treatment for hepatitis B.
In this study, we studied the anti-HBV function of
IFN-α delivered by an expressing vector pSecTagB. We
found recombinant vector pSecTagB-IFN-α could ex-
press IFN-α efficiently in hepatocytes, and this endogen-
ously expressed IFN-α exhibited stronger anti-HBV
activity than exogenously added human IFN-α.
Results
hIFN-α is efficiently expressed in hepatocytes transfected
with recombinant pSecTagB-IFN-α vector
In order to investigate whether human IFN-α (hIFN-α)
could be efficiently expressed in hepatocytes transfected
with pSecTagB-IFN-α vector, HBV positive cell line
HepG2.2.15, which chromosome was integrated by HBV
genome, and its parental cell line HepG2 were treated
with this recombinant vector. The data showed hIFN-α
was successfully transcripted (Figure 1A) and produced
(Figure 1B) in the two kinds of hepatoma cells transfected
with pSecTagB-IFN-α vector. From Figure 1B we found
the concentration of hIFN-α produced by HepG2 and
HepG2.2.15 cells was 44 and 60 pg/mL, respectively, 24 h
post of pSecTagB-IFN-α vector treatment. Cell prolifera-
tion assays demonstrated that delivering pSecTagB-IFN-α
Figure 1 hIFN-α was efficiently expressed in hepatocytes
transfected with recombinant pSecTagB-IFN-α vector. HepG2
and HepG2.2.15 cells were transfected with pSecTagB-IFN-α or
empty plasmid at a final concentration of 1 μg/mL and 1.6 μg/mL,
respectively. (A) After 48 h, RNAs were isolated as described in
Materials and Methods, and RT-PCR analysis was performed to
evaluate pSecTagB-IFN-α transfection efficiency. One representative
of three independent experiments was shown. (B) The supernatants
were harvested after 24 h, 48 h and 72 h. The level of IFN-α was
measured by ELISA. Data are expressed as the mean ± SD from at
least three independent experiments.
Yu et al. Virology Journal 2013, 10:270 Page 3 of 10
http://www.virologyj.com/content/10/1/270couldn’t affect the growth of hepatoma cells (Additional
file 1: Figure S1). Therefore, the influence of cell number
on the content of IFN-α in the supernatants and
HBV load in the following experiments was excluded.
These results suggested that this recombinant eu-
karyotic expression vector could express hIFN-α effi-
ciently in hepatocytes.
pSecTagB-IFN-α inhibits HBV replication
Interferon remains a benchmark therapy for CHB [13].
We further investigated whether pSecTagB-IFN-α could
play anti-HBV role by an autocrine hIFN-α pathway.
HepG2.2.15 cells were transfected with pSecTagB-IFN-α
vector or empty vector, and then HBV replication level
was evaluated. As shown in Figure 2A,B the mRNA
levels of HBs and HBc was decreased to 64% and
68%, respectively, 24 h post of treatment; HBV DNA
load (Figure 2C) and the contents of HBsAg and
HBeAg (Figure 2D,E) were also reduced significantly
by pSecTagB-IFN-α transfection. These results indi-
cated that pSecTagB-IFN-α vector could suppress HBV
life activities.pSecTagB-IFN-α activates JAK-STAT signal pathway and
promotes the induction of IFN-stimulated genes
JAK-STAT pathway is the most crucial one in IFN-α-
activated signaling pathways. STAT1 and STAT2 are
important transcriptional factors of JAK-STAT pathway,
and the phosphorylated STATs translocate to the nu-
cleus and direct the transcription of hundreds of IFN-
stimulated genes [19]. So, we further assessed whether
transfection of pSecTagB-IFN-α vector could activate
JAK-STAT pathway. By qRT-PCR and western blot ana-
lysis, we found that the levels of STAT1 and p-STAT1
were up-regulated in HepG2 cells and HepG2.2.15 cells
by pSecTagB-IFN-α vector transfection (Figure 3A,B).
Additionally, typical IFN-α-induced antiviral effectors,
including ISG15, OAS-1 and IFIT-3, were also increased
in HepG2 and HepG2.2.15 cells significantly (Figure 3C).
These results suggested that JAK-STAT pathway was ac-
tivated by transfection with human IFN-α expressing
vector.
Some dsRNA sensing receptors are up-regulated by IFN-α
over-expression
As a ligand of dsRNA receptor, double-stranded (ds)
RNA is synthesized during the replication of DNA and
RNA viruses. The recognition of dsRNA by its receptor
leads to the production of type I IFN, which is important
for the elimination of viruses [20]. Recent studies have
uncovered that type I IFN can enhance the sensitivity to
influenza virus by up-regulating dsRNA receptors which
may contribute to the clearance of virus [21]. It has been
reported that IFN-α stimulate the expression of TLR3,
PKR, RIG-I and MDA-5 in keratinocytes [22]. We there-
fore assumed whether the expression of dsRNA recep-
tors in hepatocytes would be increased by transfecting
human IFN-α expressing vector. As expected, the
mRNA levels (Figure 4A,B) of RIG-I, MDA-5, LGP2,
PKR and TLR3, especially RIG-I and MDA-5, were in-
creased in HepG2 and HepG2.2.15 cells by the transfec-
tion of pSecTagB-IFN-α vector, as well as the protein
levels of RIG-I and MDA-5 (Figure 4C). These data sug-
gested that some dsRNA sensing receptors were up-
regulated by over-expression of IFN-α.
Endogenously expressed IFN-α is more effective in
inhibiting HBV than exogenously supplemented IFN-α
To compare the anti-HBV effects between endogenously
expressed IFN-α and exogenously added IFN-α, HepG2.2.15
cells were transfected with pSecTagB-IFN-α vector, or
treated with recombinant hIFN-α at the dose of 30 IU/mL
(~80 pg/mL) or 60 IU/mL, which was similar or twice the
content of hIFN-α in the supernatant from HepG2.2.15
cells transfected with pSecTagB-IFN-α vector for 48 h.
Then, HBV replication ability was assessed. The results
showed the exogenous hIFN-α didn’t show significant
Figure 2 pSecTagB-IFN-α inhibited HBV replication. (A, B) HepG2.2.15 cells were transfected with pSecTagB-IFN-α or empty plasmid, and
RNAs were collected after 24 h, 48 h and 72 h. The mRNA levels of HBs and HBc were measured by qRT-PCR. (C) HBV DNA level was quantified
by fluorescence real-time PCR. (D, E) The supernatants were harvested after 24 h, 48 h and 72 h. HBsAg and HBeAg levels were assessed by
ELISA. All histograms show mean values from three independent experiments and are expressed as the mean ± SD. *P < 0.05: versus empty
plasmid transfected group.
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however, endogenously expressed hIFN-α display stronger
anti-HBV effect than exogenous hIFN-α which was
even at the dose of 60 IU/mL, accompanied with the
down-regulation of mRNA levels of HBx, HBs and
HBc (Figure 5A-C) and HBV DNA load (Figure 5D), as
well as the contents of HBsAg and HBeAg (Figure 5E,F).
These data showed that transfection of IFN-α plasmid
could be more efficient in suppressing HBV than exogenous
recombinant hIFN-α.
Lamivudine combined with pSecTagB-IFN-α displays
enhanced anti-HBV effect than with exogenously
supplemented IFN-α
Lamivudine, a nucleoside analogue available for HBV
treatment, is restricted by the high incidence of resistance
[23]. It is noteworthy that the combination of lamivudine
and IFN-α can induce a more meaningful antiviral effect
than lamivudine monotherapy [24]. Subsequently, we fur-
ther examined whether the combination of endogenously
expressed hIFN-α and lamivudine could play augmented
anti-HBV effect. As shown in Figure 6, HepG2.2.15 cells
were transfected with pSecTagB-IFN-α and treated with
lamivudine simultaneously, or treated with IFN-α2a
(30 IU/ml) combined with lamivudine. The results showed
that lamivudine combined with pSecTagB-IFN-α transfec-
tion would display a stronger anti-HBV effect at a certain
degree than with exogenous hIFN-α (Additional file 3:
Figure S3), which was characterized by a reduction ofHBx, HBs and HBc mRNA (Figure 6A-C), and lower
level of HBV DNA load (Figure 6D), and a decline in
HBsAg and HBeAg (Figure 6E,F). These findings sug-
gested that the combination of endogenous hIFN-α and
lamivudine might be beneficial for anti- HBV treatment.
Discussion
To date, IFN-α is widely used in clinical therapy for pa-
tients with chronic hepatitis B [25]. However, there are
many limitations attenuating the curative effect of IFN-α,
such as short half-life, serious side effects and instable
plasma drug concentration [26]. It is necessary to develop
new strategies to overcome these restrictions. In recent
years, there are many significant developments about
the concept of taking gene therapy as an approach in the
treatment of disorders [27], and many advantages in the
field of gene therapy, such as targeted drug delivery and
continuous infusion, have made it possible that gene ther-
apy play an increasing important role in clinical applica-
tion [28]. In the present study, in an attempt to get better
therapeutic effect for HBV, a recombinant eukaryotic ex-
pression vector encoding human IFN-α was used.
The experimental results demonstrated that human
hepatocytes treated with human IFN-α expressing vec-
tor pSecTagB-IFN-α resulted in the secretion of IFN-α
(Figure 1), concomitant with the decreased HBV replication
(Figure 2). Mechanism research showed the induction of
typical antiviral proteins (Figure 3), and the up-regulation




































































































































Figure 3 pSecTagB-IFN-α activated JAK-STAT signal pathway and promoted the induction of IFN-stimulated genes. The pSecTagB-IFN-α
or empty plasmid was transfected into HepG2 cells and HepG2.2.15 cells at a final concentration of 1 μg/mL and 1.6 μg/mL, respectively. (A)
After 24 h, the mRNA levels of STAT1 were measured by qRT-PCR. Data are expressed as the mean ± SD from at least three independent
experiments. *P < 0.05, **P < 0.01: versus empty plasmid transfected group. (B) Protein levels were evaluated by western blot. One representative
of three independent experiments was shown. (C) Western blot analysis of the protein levels of ISG15, OAS-1 and IFIT-3 in HepG2 cells and
HepG2.2.15 cells were performed after transfected for 48 h. These experiments were repeated at least three times.
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the anti-HBV effect of pSecTagB-IFN-α with exogenously
added IFN-α, and the results indicated that pSecTagB-
IFN-α exhibited stronger anti-HBV effect than exogen-
ously added hIFN-α at the dose of 60 IU/mL, which was
two times of the content of IFN-α produced by pSecTagB-
IFN-α- transfected HepG2.2.15 cells (Figure 5).
Lamivudine, the first oral nucleotide analogue ap-
proved for CHB patients, is beneficial to HBeAg sero-
conversion, normalization of ALT, inhibition of HBV
replication and slowdown of fibrosis [29]. In spite ofhigh rate of drug resistance, so far, lamivudine is the
most widely used nucleoside analogues for HBV treat-
ment owing to its low price, safety and effectiveness
[30]. Many previous studies reported that a combination
of IFN-α and lamivudine achieved some therapeutic ef-
fects [31,32]. Here, in comparison to the treatment with
exogenously added hIFN-α combined with lamivudine,
the combination of endogenously expressed hIFN-α and
lamivudine could restrain HBV more effectively at a cer-
tain degree (Figure 6). In addition, our study showed the
elevated levels of MHC I and Fas in HCC cells transfected
Figure 4 Some dsRNA sensing receptors were up-regulated
after IFN-α over-expression. (A, B) HepG2 cells and HepG2.2.15
cells were transfected with pSecTagB-IFN-α or empty plasmid as
previously described. Histogram showed the relative mRNA
expression of RIG-I, MDA-5, LGP2, PKR and TLR3 by qRT-PCR after
transfected for 48 h. Data are expressed as the mean ± SD from at
least three independent experiments. * P < 0.05: versus empty
plasmid transfected group. (C) Western blot analyzed the activation
of RIG-I and MDA-5 by delivering pSecTagB-IFN-α into HepG2 cells
and HepG2.2.15 cells after 48 h. One representative of three
independent experiments was shown.
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might enhance T cell-mediated immune responses.
In view of these, we speculate that the autocrine path-
way of human IFN-α in hepatocytes may be a more effi-
cacious therapeutic method for HBV treatment than
exogenous hIFN-α. Through liver cell specific expression
vector which contain hepatocyte specific α-fetoprotein
(AFP) promoter [33], endogenous expression of IFN-α
may display therapeutic value in the treatment of CHB,
inhibiting the replication of HBV and resulting in a re-
duction of hepatic inflammation, slowing the process of
chronic liver injury. At the same time, it provides a new
approach for HBV treatment based on the combination
of gene therapy and the traditional drug therapy.Conclusion
Endogenous expression of human IFN-α possess the fea-
ture to inhibit HBV more efficaciously and enduringly.
These observations might have therapeutic value in the
treatment of chronic HBV infection.Materials and methods
Cell line and plasmids
Human hepatoma cell lines HepG2 and HBV-positive
HepG2.2.15 cells conserved in our laboratory were cul-
tured in DMEM (GIBCO/BRL, Grand Island, N.Y. USA)
containing 10% fetal bovine serum in a humidified incu-
bator with 5% CO2 at 37°C. The empty expression vector
pSecTagB was obtained from Invitrogen (CA, USA). The
recombinant vector (pSecTagB-IFN-α) which contains
IFN-α1 cDNA was constructed in our laboratory.Transfection
HepG2 or HepG2.2.15 cells were seed at a density of
2.0 × 105 cells/mL, and then transfected with pSecTagB-
IFN-α or empty plasmid using Lipofectamine™ 2000
(Invitrogen, CA, USA) according to the manufacturer’s in-
struction. The final concentration of plasmid was 1 mg/
mL in HepG2 cells and 1.6 mg/mL in HepG2.2.15 cells.Reverse transcriptase polymerase chain reaction
(RT-PCR) assay
Total RNA was extracted by Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The concentration and quality of the extracted
RNA were determined by measuring light absorbance at
260 nm (A260) and a ratio of (A260/A280). cDNA was
synthesized from 3 μg RNA using M-MLV reverse tran-
scriptase (Promega, Madison, USA), and PCR was
performed in a total volume of 25 μL as depicted previ-
ously [34]. DNA sequences of primers (forward primer;
reverse primer) were β–actin (GTGGGGCGCCCCAGGC
ACCA, CTCCTTAATGTCACGCACGA), IFN-α (TTAG
GATCCATGGCCTCGCCCTTT, CGCGAATTCGTTATT
CCTTCCTCC).Western blot
Cells were harvested 24 h or 48 h after transfecteion of
pSecTagB-IFN-α or empty plasmid. Then, proteins were
extracted by Total Protein Extraction Kit (BestBio
Shanghai, China). Western blot analysis was performed
as previously described [35]. Antibodies for ISG15,
STAT-1, p-STAT1, MDA-5 and RIG-I were obtained
from Cell Signaling Technology (NewEngland BioLabs
Inc.); and antibody for β-actin, OAS-1 and IFIT-3 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
Figure 5 Endogenously expressed IFN-α was more effective in inhibiting HBV than exogenous IFN-α. (A-C) HepG2.2.15 cells were
transfected with pSecTagB-IFN-α or treated with IFN-α2a at the dose of 30 IU/ml or 60 IU/ml,and then RNAs were isolated after 24 h and 48 h.
The mRNA levels of HBx, HBs and HBc were quantified. (D) HBV DNA load was quantified by fluorescence real-time PCR. (E, F) HBsAg and HBeAg
levels were tested by ELISA. Data represented of three independent experiments and are expressed as the mean ± SD. *P < 0.05: versus IFN-α2a
stimulated group.
Yu et al. Virology Journal 2013, 10:270 Page 7 of 10
http://www.virologyj.com/content/10/1/270Real-time PCR
Real-time fluorescence quantitative PCR (qRT-PCR) was
performed using the SYBR Green Realtime PCR Master
Mix (Code No. QPK-201, Toyobo, Japan). Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used as
an internal standard for the quantification of the PCR.
The primers were synthesized by the Beijing Genomics
Institute (Beijing, China) and listed in Table 1.Analysis of HBV DNA
Viral particles in the supernatants were quantified by
fluorescence real-time PCR according to the instructions
of the kit for Quantification of HBV DNA (Da-An,
Guangzhou, China).ELISA
Supernatants were harvested from HCC cells after
transfected with pSecTagB-IFN-α or empty plasmid, and
the amounts of HBeAg and HBsAg were detected by
ELISA kit from RongSheng Biotechnology (Shanghai,
China). The level of IFN-α was quantified using ELISA
kits from XiTang Biotechnology (Shanghai, China). As-
says were performed according to the manufacturer’s
instruction.Cell proliferation assay
All cellular growth assays were performed in 96-well
plates. HepG2 cells were seed at a density of 5 × 103
cells/well and HepG2.2.15 cells were seed at a density of
1 × 104 cells/well, followed by transfection of pSecTagB-
IFN-α or empty plasmid using Lipofectamine™ 2000
according to the manufacturer’s description. The final
concentration of plasmid was 1 mg/mL in HepG2 cells
and 1.6 mg/mL in HepG2.2.15 cells, and then incubated
for indicated time. Next, 15 μL MTT (10 mg/mL, Sigma,
St Louis, MO, USA) solution was added, and the plates
were incubated for a further 4 h at 37°C. After centrifu-
gation, MTT solution was then eliminated, and 200 μL
dimethyl-sulfoxide (DMSO; Sigma, St Louis, MO, USA)
was added to each well to dissolve the formazan crystals.
The absorbance at 570 nm (A570) in each well was con-
firmed by a scanning multi-well spectrophotometer.
Flow cytometry
Immunofluorescence staining was performed using stand-
ard protocols. HCC cells were transfected with pSecTagB-
IFN-α or empty plasmid for 48 h. The expression of cell
surface MHC I and Fas were determined by flow cytome-
try. Briefly, the cells were washed twice in washing buffer
(PBS) and resuspended in 200 μL PBS before incubation
Table 1 Primers used for real-time PCR



















Figure 6 Lamivudine combined with pSecTagB-IFN-α displayed enhanced anti-HBV effect than with exogenously supplemented IFN-α.
(A-C) HepG2.2.15 cells were transfected with pSecTagB-IFN-α and treated with lamivudine (3 μmol/L), or treated with IFN-α2a (30 IU/mL) and
lamivudine (3 μmol/L). Then, RNAs were extracted after 24 h and 48 h. The relative mRNA expression of HBx, HBs and HBc were examined by
qRT-PCR. (D) The level of HBV DNA was quantified by fluorescence real-time PCR. (E, F) The contents of HBsAg and HBeAg were detected by
ELISA. Data are expressed as the mean ± SD from at least three independent experiments. *p < 0.05: versus the combination of exogenous IFN-α2a
and lamivudine stimulated group.
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and PEcy5-conjugated anti-Fas (BD Pharmingen, USA) for
40 min at 4°C. Results were analyzed by FACS Calibur™
and CELL Quest™ software (Becton Dickinson, Mountain
View, CA, USA).
Statistical analyzes
All data are expressed as mean ± SD and accompanied
by at least three distinct experiments. Statistical analysis
was determined by a paired Student’s t-test and *P < 0.05,
**P < 0.01 were considered statistically significant.
Additional files
Additional file 1: Figure S1. Effect of pSecTagB-IFN-α on the
proliferation of hepatocytes. HepG2 cells and HepG2.2.15 cells were
transfected with pSecTagB-IFN-α as described in Materials and Methods.
The growth of these HepG2 and HepG2.2.15 cells were tested by MTT
assay. These experiments were repeated at least three times.
Additional file 2: Figure S2. Exogenous IFN-α couldn’t evidently play a
role in suppressing HBV. HepG2.2.15 cells were stimulated with IFN-α2a at
a dose of 30 IU/mL or 60 IU/mL, respectively. Then, RNAs were collected
after 24 h and 48 h. The mRNA levels of HBx, HBs and HBc were quantified
by qRT-PCR. Data represented of three independent experiments and are
expressed as the mean ± SD. *p < 0.05: versus HepG2.2.15 or IFN-α2a
stimulated group.
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http://www.virologyj.com/content/10/1/270Additional file 3: Figure S3. Exogenous IFN-α combined with
lamivudine didn’t exhibit obviously increased anti-HBV function.
HepG2.2.15 cells were stimulated with lamivudine (3 μmol/L) and IFN-α2a
(30 IU/mL) simultaneously. Then, RNAs were isolated after 24 h and 48 h.
The relative mRNA levels of HBx, HBs and HBc were examined by qRT-
PCR. Data are expressed as the mean ± SD from three independent
experiments. *p < 0.05: versus HepG2.2.15 or lamivudine stimulated
group.
Additional file 4: Figure S4. pSecTagB-IFN-α up-regulated the
expression of MHC I and Fas. HepG2 cells and HepG2.2.15 cells were
transfected with pSecTagB-IFN-α as previously described. After 48 h, the
expressions of MHC I and Fas were tested by flow cytometry analysis.
One representative of three independent experiments was shown.
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